Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

ALEC Price Correlated With Financials For Alector

Free historical financial statements for Alector Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 12 quarters since 2019. Compare with ALEC stock chart to see long term trends.

ALEC Stock Compared to Quarterly

ALEC Income Statement

Revenue, Net:13994000
Revenue Per Share:0.1706
Research & Development Expense:52790000
Total Operating Expenses:69723000
Operating Income:-55729000
Net Income:-55608000
Earnings Per Share, Basic:-0.66
Shares Outstanding, Basic Avg:82039774

ALEC Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1594000
Net Cash from Operations:-49265000
Net Cash from Operations Per Share:-0.6005
Net Cash from Financing Activities:8638000
Property, Plant & Equipment Purchases:557000
Net Cash from Investing Activities:-146753000
Net Change in Cash & Equivalents:-187380000

ALEC Balance Sheet

Cash and Cash Equivalents:330624000
Short-Term Investments:406099000
Total Current Assets:749713000
Property, Plant & Equipment, Net:27330000
Total Assets:814658000
Accounts Payable:4749000
Total Short-Term Liabilities:139555000
Total Liabilities:513934000
COMPANY PROFILE
1. The Company and Liquidity

Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Initial Public and Follow-on Offerings On February 7, 2019, the Company completed an initial public offering (IPO) through issuing and selling 9,739,541 shares of common stock at a public offering price of $ 19.00 per share, including 489,541 shares sold pursuant to the underwriters’ partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $ 168.2 million, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. On January 30, 2020, the Company completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $ 25.00 per share, including 1,252,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $ 224.5 million, after deducting underwriting discounts and commissions and estimated offering costs.

Data imported from Alector Inc SEC filings. Check original filings before making any investment decision.